Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel and XPartners in connection with the acquisition of NXTLEV
Mandate

Vinge advises Axcel and XPartners in connection with the acquisition of NXTLEV

February 14, 2024 M&A Real Estate and Construction

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of NXTLEV Holding AB and its subsidiaries (”NXTLEV”).

NXTLEV specialises in the building and construction industry and offers qualified services within project management, design management, construction management, etc. NXTLEV is involved in several major projects including, among others, the capacity increase of Saltsjöbanan, Spårväg Syd, Förbifart Stockholm, Södertälje Sluss and Kanal.

Vinge's team consisted of partner Christina Kokko together with Karl Klackenberg, Carl Fredrik Wachtmeister, Gustav Persson, Egil Svensson, Sara Passandideh, Filip Magnusson and Alexander Rüdén (M&A), Clara Klingspor (Construction) and Cecilia Loctander (Transaction Support Co-ordinator).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025